Top Markets
#1 Wibx Wibx +3.22%
#2 BOT BOT +2.51%
#3 TronBank TronBank +2.45%
#4 Cysic Cysic +2.29%
#5 Starpower Starpower +2.10%
#6 Wiki Cat Wiki Cat +2.02%
#7 The Bitcoin Bull The Bitcoin Bull +1.56%
#8 Tokamak Network Tokamak Network +1.53%
#9 Audiera Audiera +1.45%
#10 SIXSEVEN SIXSEVEN +1.17%
Coin of the day
Wibx Wibx
Settings
Language
ENGLISH
Currency
USD
Theme
PhoenixBio Co., Ltd. PhoenixBio Co., Ltd.

PhoenixBio Co., Ltd.

6190
Rank in Stocks #32811
PhoenixBio Co., Ltd. delivers specialized contract research services to support... PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.
Share Price
$2.22
Last synced: 2026-08-17
Market Cap
$9.03M
Change (1 day)
-3.13%
Change (1 year)
-24.26%
Country
JP
Trade PhoenixBio Co., Ltd. (6190)

Category

Healthcare
P/E ratio for PhoenixBio Co., Ltd. (6190)
P/E ratio as of 2026 TTM: 0
According to PhoenixBio Co., Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for PhoenixBio Co., Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.